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Protein phosphatase type 1 (PP1)1 is involved in a wide range of
cell activities (1), and even within the more restricted theme of
contractile activity in muscle several processes may be considered.
Important areas include regulation of ion channels (2), effect of
phospholamban on Ca2 uptake by the SR (3), and phosphoryla-
tion-dephosphorylation of myosin II.
Phosphorylation of myosin light chains (located in the head-neck
junction of the myosin molecule) by the Ca2-calmodulin-depend-
ent MLCK in all muscle types is established (4). Discovery of
MLCK spurred numerous reports on the phosphatases involved. In
smooth muscle, phosphorylation of myosin II increases actin-acti-
vated ATPase activity and is required for contraction (4). Much of
the earlier work focused on smooth muscle myosin phosphatase
(MP). An initial controversy was the type of catalytic subunit
involved, i.e. PP1c, PP2Ac, etc. In smooth muscle the majority of
MP activity is due to PP1c (5), and this finding was extended to
include skeletal and cardiac muscle. Three genes encode PP1c: , ,
and  (also called ). Five PP1c isoforms are expressed, where 1/2
and 1/2 are generated by alternative splicing (1). To accommodate
specific functions of the limited number of PP1c isoforms with the
multiple roles of PP1c the concept of target subunits was developed.
Over 50 potential target subunits have been identified (1) that in
complex with PP1c may designate specific substrates, regulate activ-
ity, and direct distinct cell localization. This review describes one of
the PP1 holoenzymes, namely the myosin phosphatase of muscle.
Smooth Muscle Myosin Phosphatase
In smooth muscle the role of MP is to dephosphorylate Ser-19
and to a lesser extent Thr-18 in P-LC20. (The PKC site, Thr-9, can
also be dephosphorylated by MP.) The current model for smooth
muscle MP is based on the gizzard holoenzyme (6, 7). The holoen-
zyme is a trimer consisting of: a catalytic subunit, PP1c; a target
subunit of 110 kDa; and a smaller subunit of 20 kDa (M20). A
scheme of the MP holoenzyme is shown in Fig. 1. The function of
M20 is not known, and the critical properties of MP can be ascribed
to the large subunit, i.e. binding of PP1c and the substrate, P-
myosin. Thus, it is termed myosin phosphatase target subunit,
MYPT1. (Other terms include M110, myosin binding subunit
(MBS), and M130/M133). Initially MYPT1 was cloned from chicken
gizzard (M130/M133 (8)) and also from rat aorta (rat3 isoform (9)).
Structure of MYPT1
From the initial reports the basic features of the MYPT1 mole-
cule were established. The molecule is hydrophilic, and no exten-
sive hydrophobic patches are found. Plans of human and chicken
MYPT1 are shown in Fig. 1. A striking feature of all MYPT iso-
forms is the presence of N-terminal ankyrin repeats. In MYPT1
each of the 7 or 8 repeats contains 33 residues with 20 residues
conserved. The 171–197 region is less homologous but shows sim-
ilarity to ankyrin repeats and was so considered in chicken M130/
M133 (8). It is suggested that the conserved sequence for ankyrin
repeats is structure-based in that it forms a -hairpin-helix-loop-
helix (22) structure (10). Based on several solved structures it is
known that both the -hairpins and the surface of the ankyrin
groove (helical bundle) can be involved in binding to target proteins
(10). Many proteins interact with ankyrin repeats (11), and thus
the proposed role for these repeats in MYPT1 is to act as an
interactive protein platform.
Flanking the N-terminal edge of the first ankyrin repeat is the
PP1c-binding motif, the “RVXF” (1) motif (residues 35–38). Some
variation is allowed and a general consensus is (R/K)X1(V/I)X2(F/
W), where X1 may be absent or be residues other than large hydro-
phobes and X2 is any residue except large hydrophobes, phospho-
serine and probably aspartic acid (1). Residues flanking the motif,
N-terminal basic residues, and C-terminal acidic residue(s) may
contribute to binding (12). In human MYPT1 the pertinent se-
quence is 30KRQKTKVKFDD. The RVXF motif is present in many
target proteins and even occurs in proteins unlikely to bind PP1c
(1). This motif interacts with PP1c in a hydrophobic groove involv-
ing residues Ile-169, Leu-243, Phe-257, Leu-289, Cys-291, and Phe-
293. Important points are that the interaction site for RVXF on
PP1c is within the invariant region for all PP1c isoforms (but not
conserved in PP2A and PP2B) and that the site is distinct from the
catalytic site. Peptides containing the RVXF motif may displace
target subunits, but binding of the RVXF motif to PP1c does not
directly influence activity (1, 13). In MYPT1 the RVXF motif
(KVKF) acts as the primary interaction site (an anchoring site) for
PP1c, but other interactions are involved (14). These include res-
idues 1–22, the ankyrin repeats (possibly repeats 5–8, sequence
167–295 (7)), and a site within the sequence 304–511. Only the
interaction with KVKF has high affinity, but the other secondary
interactions are important in that they may modify PP1c proper-
ties. For example, interaction of PP1c or P-myosin with the N-
terminal segment of MYPT1 could activate PP1c. These multiple
and hierarchical interactions form a combinatorial control of PP1c
(13), and considering these, it is likely that PP1c is pivoted via the
RVXF motif and clasped by the N-terminal sequence of MYPT1 and
the ankyrin repeats. Other structural features of MYPT1, includ-
ing some phosphorylation sites, are shown in Fig. 1.
Interactions with MYPT1
A potentially important feature of MYPT1 as a target subunit is
that it is a platform for multiple interactions. The binding of
myosin to MYPT1 is an important but controversial point. One
view is that P-myosin or P-LC20 binds to the ankyrin repeats,
possibly repeats 6–8 (15). Interaction of the phosphorylated sub-
strate with the catalytic site of PP1c is expected with an added
contribution to binding by the ankyrin repeats. Dephosphorylated
substrate binds less effectively, and in the presence of ATP only
P-myosin or P-LC20 is bound (7). The opposing view is that dephos-
phorylated myosin binds to the C-terminal sequence of MYPT1
(excluding the C-terminal 72 residues (16) in the chicken isoforms).
Binding to both the N-terminal and C-terminal regions of MYPT1
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is feasible if P-LC20 (in the myosin S2 region) binds to the N-
terminal sites and the rod portion of myosin binds to the C-termi-
nal sites. It was suggested that phosphorylation of Thr-850
(chicken M133) by ROK reduced binding of MYPT1 to myosin (17).
Adducin (, ,  (18)) and Tau and MAP2 (19) also bind to the
ankyrin repeats and are phosphorylated and dephosphorylated by
ROK and MP, respectively.
Multiple interactions with the ankyrin repeats are expected (11),
but what is surprising is that the C-terminal half of MYPT1 also
interacts with many molecules (20). M20 binds to the C-terminal
region of MYPT1, residues 934–1006 of human MYPT1, in an
interaction not involving LZ repeats (15, 16). M20 also binds to
myosin but not PP1c (16). GTP-RhoA (but not inactive GDP-RhoA)
binds to the C terminus and could represent an alternative docking
site for GTP-RhoA in addition to the plasmalemma. Acidic phos-
pholipids target residues 667–1004 of chicken M133 (does not con-
tain LZ sequences) and inhibit PP1c activity (7). This binding/
inhibition of MP activity is reversed on phosphorylation of MYPT1
by PKA. Moesin also binds to MYPT1 via the C-terminal part (18).
Other interactions involve the LZ motifs in some isoforms of
MYPT1 and include: 1) interaction of the LZ motifs of cGMP-de-
pendent kinase (cGKI) and MYPT1 (21); 2) binding of the PDZ2
domain of interleukin-16 precursor proteins to the C-terminal 30
residues of MYPT (22); and 3) interaction of a coiled-coil domain in
RhoA-interacting protein (expressed in vascular smooth muscle)
with the LZ motifs of MYPT1 (23).
The many interactions involving MYPT1 suggest several sub-
strates and a possible targeting function in other macromolecular
complexes and thus a much broader role in cell function than only
dephosphorylation of P-myosin. This complexity may reflect the
varied cell localizations observed with MYPT1 on filaments and
membranes (20). In differentiated striated muscle cells MYPT may
have a more restricted role.
MYPT Family
Several isoforms of MYPT12 are generated by cassette-type al-
ternative splicing of single gene pre-mRNAs and involve the pres-
ence or absence of central inserts and the C-terminal LZ motifs.
The M130/133 chicken gizzard MYPT1 isoforms differ by a 123-
nucleotide insert (residues 512–552 of M133 (8)) arising from a
single exon (24). In rat the situation is more complex, and 5 central
insert isoforms are generated (24) resulting from differing expres-
sion of 2 exons. Control of this central region (in chicken) is exerted
by a cis-enhancer complex close to the alternative exon 5-splice
site (25). In addition, isoforms are generated by cassette-type al-
ternative splicing of a 3-exon (31 nucleotides). Skipping of this
exon codes for the LZ-positive MYPT1, and inclusion of the exon
introduces a premature stop codon and codes for the LZ-negative
MYPT1 (26). Thus many isoforms of MYPT1 can be generated and
to some extent are expressed in a tissue-specific fashion (24, 26).
Recently several molecules similar to MYPT1 have been de-
scribed (Fig. 2). Each has the N-terminal ankyrin repeats and the
RVXF motif. The C-terminal half is more variable. As originally
cloned (27) MYPT2 (human chromosome 1q32) contained 982 res-
idues (110 kDa), and subsequently a second isoform (MYPT2B) was
recognized from the genomic organization of the MYPT2 gene (28).
These arise from alternative splicing of exon 24, each isoform
reflecting the inclusion of either exon 24 (MYPT2B) or exon 25
(MYPT2A). Both contain C-terminal LZ motifs. A comparison of
MYPT1 and MYPT2A is shown in Fig. 2. Overall identity is 52%
but several areas are more conserved (Fig. 2). The N-terminal
sequences (1–57 of MYPT2 and 1–38 of MYPT1) are distinct (36%
identity) although both contain the PP1c-binding motif. MYPT1
may be considered a housekeeping gene and is expressed in most
tissues but is higher in smooth muscle ([MYPT1] in rabbit portal
vein is 1.2 M).3 MYPT2 is more restricted with both A and B
isoforms found in heart, skeletal muscle, and brain and predomi-
nantly MYPT2A in other tissues (28).
Another member of the MYPT family is MBS85 (29). This is
widely distributed with higher levels in the heart. MBS85 binds
specifically to the PP1c isoform and also binds and dephosphory-
lates P-myosin (or P-LC20). Phosphorylation of Thr-560 by myo-
tonic dystrophy kinase-related Cdc42-binding kinase or ROK is
required for its binding to PP1c and inhibition of phosphatase
activity (29). MYPT3 has some similarity to MYPT1/2 (Fig. 2) but
only in its N-terminal half (30). Other features are shown in Fig. 2.
A putative regulatory site is not present. MYPT3 inhibited the
activity of PP1c with phosphorylase a and P-myosin in contrast to
activation of PP1c by MYPT1 with P-myosin. MYPT3 is widely
distributed (mouse) and appears in high amounts in heart, brain, and
kidney. TIMAP is similar to MYPT3 (45% identity) and contains
the “marker” N-terminal structure, conserved nuclear localization
signal and a C-terminal CAAX box (31). It shows high expression in
endothelial and hematopoietic cells. Analysis of genomic data bases
indicates that several gene products homologous to MYPT3 and
TIMAP exist (30, 31).
Each family member binds PP1c via the RVXF motif, and the
binding of PP1c and substrate may be augmented by the ankyrin
2 The Human Gene Nomenclature Committee has assigned the following:
PPP1R12 A, B, or C for MYPT1, MYPT2, and MBS85, respectively; PPP1R16
A or B for MYPT3 and TIMAP, respectively; and PPP1R14A for CPI-17. Gene
location is listed on www.gene.ucl.ac.uk/cgi-bin/nomenclature/searchgenes.
pl using PPP1R* as query. 3 T. M. Butler, and M. J. Siegman, personal communication.
FIG. 1. Plans of the human and chicken (M133) MYPT1 molecules
(upper) and the human myosin phosphatase holoenzyme (lower).
Regions of MYPT1: KVKF, PP1c-binding motif; a, ankyrin repeat; D/E,
acidic region; /, ionic region; S/T, Ser- and Thr-rich region; L, leucine
zipper. Residue numbers are given and some phosphorylation sites are
indicated (bold). For the holoenzyme, interactions of varying strengths be-
tween MYPT1 and PP1c are indicated (see text). Suggested binding sites for
phosphorylated light chain and myosin are indicated by arrows.
FIG. 2. MYPT family. Percentages in parentheses give amino acid identity
to MYPT1. For MYPT1, MYPT2, and MBS85, percent identities for distinct
regions and positions of suggested inhibitory phosphorylation sites (bold) are
shown. Regions: PP1c-binding motif, red area at N-terminal edge of ankyrin
(a) repeats; WM, Walker motif (nucleotide-binding site); CaaX, putative
prenylation site. For MYPT3 two SH3 motifs shown. This figure was
adapted from Ref. 20 with permission.
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repeats. The C-terminal region is adapted for a given function, e.g.
regulation or binding of other ligands or attachment to membranes
(via the prenylated C terminus). However, the function(s) of most
MYPT family members is not known. Even with MYPT1 and MYPT2
it is possible that substrates other than P-myosin are implicated.
Small MP Subunit (M20)
M20 was cloned from chicken gizzard (9), and two splicing vari-
ants of 161 (M18) and 186 (M21) residues were detected (32). Only
M21 contains C-terminal LZ motifs. Expression of each isoform is
tissue-specific (32). Part of M20 arises from the MYPT2 gene (33),
and two heart-specific isoforms of M20 arise from the MYPT2A and
MYPT2B genes involving exons 14–25 (28). M20 was not detected
in either brain or skeletal muscle (20). The function of M20 is not
established. Suggested roles (20) include: modification of Ca2
sensitivity in renal artery and cardiac myocytes; binding to the
myosin dimer; and a role in microtubule dynamics. The binding of
M20 to MYPT1 does not affect phosphatase activity (7).
Regulation of MP Activity
Early studies assumed that MP activity was unregulated, but
more recently inhibition and activation have been documented. At
fixed suboptimal [Ca2] inhibition of MP would increase [P-myosin]
and activation would decrease [P-myosin], resulting in Ca2 sen-
sitization and Ca2 desensitization, respectively.
More data are available for Ca2 sensitization. Inhibition of MP
was found to be linked to agonist stimulation via numerous tri-
meric G protein-coupled receptors (list given in Ref. 34), and RhoA
and thus Rho-associated kinase, ROK, are important downstream
links (7, 34). There are two isoforms of ROK (ROK/ROCKII and
ROK/ROCKI (18) with 32% identity). ROK was isolated from
chicken gizzard smooth muscle (35). There are several mechanisms
proposed for inhibition of MP (7, 20), i.e. phosphorylation of
MYPT1; phosphorylation of an inhibitory protein, CPI-17; dissoci-
ation of the holoenzyme; and translocation and subsequent disso-
ciation of the holoenzyme. The first two are cited more frequently.
Initially it was found that incubation of permeabilized portal
vein with ATPS induced Ca2 sensitization, inhibition of MP, and
thiophosphorylation of MYPT1 (see Refs. 7 and 20). Subsequently,
it was shown that phosphorylation of MYPT1 at Thr-695 (Thr-696
in human MYPT1) by an endogenous kinase inhibited gizzard MP
activity. ROK was the first known kinase shown to phosphorylate
MYPT1 (7, 20), and two major sites, Thr-696 and Thr-853 (20, 36),
and several minor sites (36) were identified. Several kinases are
now known to phosphorylate MYPT1 (20), many at the inhibitory
site. The endogenous kinase was identified and termed MYPT1
kinase (previously ZIP-like kinase (37)). Some of these kinases
(ROK, MYPT1 kinase, and ILK) can also directly phosphorylate
LC20 at Ser-19 and have been implicated in Ca2-independent
contractile events, particularly in non-muscle cells. The relevance
of multiple kinases that phosphorylate the inhibitory site is not
known but may represent the convergence of different pathways at
MYPT1, e.g. Rac-1/myotonic dystrophy protein kinase, Rac or
Cdc42/p21-activated kinase, and Ras/Raf-1. The molecular basis
for inhibition of MP as a result of phosphorylation is not under-
stood. The inhibition with several substrates is due largely to a
decrease in Vmax. Dissociation of MP following phosphorylation is
unlikely (20). For intramolecular inhibition (autoinhibition) folding
of the molecule is expected to allow interaction of Thr-696 with the
N-terminally located PP1c. However, it should be pointed out that
sequences around both Thr-696 and Thr-853 are similar to that
around Ser-19 of LC20 (from 3 to 6). Intermolecular inhibition
also could occur via formation of head-to-tail dimers of MYPT1 (20).
CPI-17 inhibits PP1. It is composed of 147 residues (17 kDa) and
expressed in smooth muscle and brain (38). In human aorta a
splicing variant is expressed that lacks sequence 68–94, encoded
by exon 2 of the 4 exons (20). Unlike other inhibitors of PP1, e.g.
inhibitors 1 and 2, CPI-17 inhibits both the catalytic subunit and
PP1 holoenzymes. Phosphorylation at Thr-38 enhances inhibitory
potency about 1000-fold, and the first kinase implicated was PKC
( and  isoforms). Subsequently several kinases, notably ROK,
were found to phosphorylate Thr-38. Residues 35–120 are required
for recognition of MP and Tyr-41 is necessary to reduce dephospho-
rylation of Thr-38 by MP (39). The solution NMR structure (40)
indicates that phosphorylation of Thr-38 induces a conformational
change that promotes specific recognition of MP by CPI-17. Hista-
mine stimulation of smooth muscle fibers caused phosphorylation
of Thr-38 that was reduced by both ROK and PKC inhibitors,
suggesting input from two signaling pathways (41).
Whether CPI-17 or MYPT1 is dominant in regulation of MP is
controversial and perhaps depends on the tissue/cell involved. Gen-
eral considerations are that MLCK and MP are lower in tonic than
phasic smooth muscle and that CPI-17 is higher in vascular com-
pared with visceral muscle (42). Several reports have suggested
that CPI-17 plays a dominant role in Ca2 sensitization in various
smooth muscles (42–44). Also, in NO-mediated vasorelaxation a
transient decrease in CPI-17 phosphorylation (Thr-38) correlated
to a transient activation of MP activity (45).
Two other phosphorylation-dependent inhibitors of PP1 are the
phosphatase holoenzyme inhibitors (PHI-1 and PHI-2 (46)) and
kinase-enhanced protein phosphatase type 1 inhibitor (KEPI (47)).
PHI-2 and KEPI are high in cardiac muscle. CPI-17 has sequence
similarity to PHI-1 and also to the C-terminal domain of Lim
kinase-2 (48).
Lipid messengers should be considered in inhibition of MP and
Ca2 sensitization. Arachidonic acid was proposed to dissociate the
MP subunits (20, 34) with inhibition reflecting the reduced activity
of isolated PP1c. An alternative explanation is that arachidonic
acid activates ROK, independent of RhoA, and this phosphorylates
either MYPT1 or CPI-17 (20). Sphingosine 1-phosphate, sphingo-
sylphosphorylcholine, and lysophosphatidic acid also activate the
ROK pathway (34).
Because phosphorylation of myosin II is critical for smooth mus-
cle function defects in the balance of phosphorylation may lead to
disorders of smooth muscle. Several implicate inhibition of MP via
the RhoA/ROK pathway, and the ROK inhibitors, Y-27632 and
HA-1077, have been widely used. Examples include hypertension,
coronary spasm, cerebral vasospasm, vasoplastic angina, and bron-
chial asthma (20, 34).
Less is known about activation of MP activity. Usually this is
associated with relaxation of smooth muscle caused by increases in
cAMP and cGMP. An exception is the activation of MP by mitosis-
specific phosphorylation of MYPT1 at Thr-435 and/or Ser-432 (in
human isoforms) thought to reflect an increase in binding to P-
myosin (49). The mechanism underlying activation of MP (initially
shown in permeabilized smooth muscle preparations (34)) by PKA
and cGK is not clear, but in general, this opposes the RhoA/ROK
pathway. Direct phosphorylation of MYPT1 by either kinase does
not activate MP (20), and thus it is assumed that additional com-
ponents are involved. One suggestion is that PKA and cGK inacti-
vate the RhoA/ROK pathway. Under in vitro conditions RhoA is
phosphorylated by PKA and cGK at Ser-188 and was reported to
inactivate RhoA (20, 34). A problem with this proposal is that
phosphorylation of RhoA under in vivo conditions was difficult to
detect although phosphorylation of non-prenylated RhoA was de-
tected in cells (50). The mechanism of RhoA inactivation may be
because of enhanced interaction of phosphorylated RhoA with GDI
(50) and/or phosphorylation of the switch I region of G13 and
reduced downstream signaling by G13 (51). Any decrease in RhoA
activation would not effect a net activation of MP but would reduce
the extent of inhibition. Activation of MP by cGKI is suggested to
require interaction of the LZs of MYPT1 and cGKI (21), and only
those smooth muscles expressing the LZ-positive MYPT1 isoforms
show cGMP-dependent Ca2 desensitization (26).
Telokin, an independent protein derived from the smooth muscle
MLCK gene, contains the C-terminal domain of MLCK (20) and
also has been implicated in cyclic nucleotide-dependent relaxation
of smooth muscle (34). It is expressed at relatively high levels
(70–80 M, i.e. about the same concentration as myosin II) only in
phasic smooth muscle. Under in vivo conditions telokin is phospho-
rylated by PKA and cGK at Ser-13 (34). Telokin also is phospho-
rylated at Ser-19, a mitogen-activated protein kinase site, but the
in vivo role for this is not known (34). The mechanism by which
telokin or phosphorylated telokin activates MP is not established.
Myosin Phosphatase in Striated Muscle
In striated muscle the target for MP is Ser-15 on the P-regula-
tory light chain. The idea that MP in skeletal muscle requires a
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different regulatory subunit than that in smooth muscle was pro-
posed by Cohen and co-workers (6). This was identified as MYPT2
based on tissue distribution (27), matching of fragments isolated
from skeletal muscle (33, 52), and the detection of the full-length
MYPT2 in rat muscle (53). In cardiac muscle, MYPT2 also is the
major targeting subunit of MP (27). In the myoblast cell line,
C2C12, a transition from MYPT1 to MYPT2 occurs as the non-
differentiated cells develop a sarcomeric phenotype (53). The func-
tion of myosin phosphorylation in striated muscle is not as pro-
nounced as in smooth muscle. In general, phosphorylation of
striated muscle myosin increases force at submaximal [Ca2], i.e. an
increase in Ca2 sensitivity, and is most pronounced in fast-twitch
muscle. It is proposed that phosphorylation of the regulatory light
chains moves the myosin head closer to the thin filament and in-
creases the transition from non-force- to force-generating states (54).
This may be a general mechanism in all muscle types. Myosin phos-
phorylation (in fast-twitch muscle) is slower than the twitch contrac-
tion but considerably faster than calculated phosphatase rates (ap-
proximately 1 s1 compared with 0.007 s1 (54)). In cardiac muscle
the rates of myosin phosphorylation and dephosphorylation are lower
(1–4% of fast-twitch muscle (54)), and effects due to myosin phospho-
rylation thus are more difficult to detect. However, in rat hearts a
positive correlation was found between myosin phosphorylation and
left ventricular pressure development (54). Transgenic mice express-
ing a non-phosphorylatable regulatory light chain showed loss of
Ca2 sensitivity and longer term structural changes (55).
A more recent possibility is that the level of myosin phosphoryl-
ation may be important in differentiation or sarcomere organiza-
tion. In C2C12 cells partial inhibition of non-muscle MLCK caused
a decrease in the numbers of larger myotubules (53), and in cardiac
myocytes MLCK mediates agonist-induced sarcomere organization
during the early hypertrophic response (56). In view of the impor-
tance of maintaining a certain level of myosin phosphorylation it is
likely that striated muscle MP is regulated, although there are no
data to indicate this.
Perspectives
Although knowledge on MP is progressing, notably acceptance of
the basic molecular structure, i.e. PP1c plus MYPT1 (in smooth
muscle) and MYPT2 (striated muscle), several questions are unan-
swered. Details of MP regulation in smooth muscle are important
to establish, both for a molecular appreciation of contractile func-
tions and to facilitate pharmaceutical intervention for many disor-
ders of smooth muscle function. In striated muscle there are no
data on regulation of MP. Several components (proteins/lipids) bind
to MYPT1, and the possibility is raised that MP is not dedicated to
P-myosin but has alternative substrates and functions. Another
intriguing area for future research is to establish the roles of the
other members of the MYPT family.
Note Added in Proof—The crystal structure of PP1c and an N-terminal
fragment of MYPT1 (residues 1–299) was reported recently (Terrak, M.,
Kerff, F., Langsetmo, K., Tao, T., and Dominguez, R. (2004) Nature 429,
780–784). This illustrates the critical interaction of the RVXF motif and
PP1c and also secondary interactions involving the N-terminal sequence
(residues 1–34) and ankyrin repeats 1, 5, 6, and 7.
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